Clinical Significance of High Expression of MiR-452-5p in Lung Squamous Cell Carcinoma
Overview
Authors
Affiliations
The role of microRNA (miRNA)-452-5p in lung squamous cell carcinoma (LUSC) remains unclear. Therefore, the present systematic study was performed to investigate the clinical significance and the rudimentary mechanism of the function of miR-452-5p in LUSC. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to confirm the expression level and clinical value of miR-452-5p in LUSC. Using online databases and bioinformatic software, gene ontology (GO), pathway and protein-protein interaction (PPI) analyses of miR-452-5p target genes were performed to examine the molecular mechanism of miR-452-5p. The association between the expression of miR-452-5p and that of its hub genes was verified using TCGA. Based on TCGA data on 387 clinical specimens, the expression of miR-452-5p in LUSC was significantly increased compared with adjacent lung tissues (7.1525±1.39063 vs. 6.0885±0.35298; P<0.001). The expression levels of miR-452-5p were significantly correlated with age (P=0.001) and tumor-node metastasis stage (P=0.028). Furthermore, the increased expression of miR-452-5p in LUSC compared with non-cancerous tissue [standard mean deviation (SMD), 0.372; 95% confidence interval (CI), 0.020-0.724; z=2.07; P=0.038] was validated by a meta-analysis of 720 clinical samples. The GO and pathway analyses revealed that miR-452-5p target genes were mainly enriched in the 'regulation of transcription', 'nucleoplasm', 'protein binding' and 'cell cycle' pathways. A total of 10 hub genes were identified by PPI analysis, and 5 hub genes (SMAD4, SMAD2, CDKN1B, YWHAE and YWHAB) were significantly enriched in the 'cell cycle' pathway. The expression of CDKN1B was negatively correlated with miR-452-5p (P=0.003). It was concluded that miR-452-5p may serve an essential role in the occurrence and progression of LUSC by targeting CDKN1B, which is involved in the cell cycle.
Mashayekhi V, Schomisch A, Rasheed S, Aparicio-Puerta E, Risch T, Yildiz D Cell Commun Signal. 2024; 22(1):344.
PMID: 38937789 PMC: 11212187. DOI: 10.1186/s12964-024-01701-y.
CircCCDC66: Emerging roles and potential clinical values in malignant tumors.
Wang X, Zhang C, Song H, Yuan J, Zhang L, He J Front Oncol. 2023; 12:1061007.
PMID: 36698408 PMC: 9869039. DOI: 10.3389/fonc.2022.1061007.
MicroRNA-452: a double-edged sword in multiple human cancers.
Dermani F, Datta I, Khoei S Clin Transl Oncol. 2023; 25(5):1189-1206.
PMID: 36622551 DOI: 10.1007/s12094-022-03041-0.
LINC01140 Targeting miR-452-5p/RGS2 Pathway to Attenuate Breast Cancer Tumorigenesis.
Li X Dis Markers. 2022; 2022:2434938.
PMID: 36299824 PMC: 9592237. DOI: 10.1155/2022/2434938.
Chen X, Dou B, An J, Feng S, Liu N, Sheng G Iran J Basic Med Sci. 2022; 25(1):46-52.
PMID: 35656441 PMC: 9118285. DOI: 10.22038/IJBMS.2021.58963.13095.